Retatrutide side effects: what TikTok skips over vs. the data

What's this video probably claiming?

Based on the caption, @sofatheloaf is describing a constellation of side effects after roughly one month on what she calls "reta" (almost certainly retatrutide, a triple GIP/GLP-1/glucagon receptor agonist that has made the rounds in peptide communities). The claim is that the wellness-focused side of TikTok glosses over the rough stretches: persistent cold sensitivity, intermittent nausea, blurry vision, fatigue, and a general "feeling off" that's hard to name. The implicit argument is that people chasing results aren't being honest about what the in-between period actually feels like. That framing, while sympathetic, also conflates several things worth separating: documented pharmacological effects, individual variation, and the very real problem that retatrutide is not FDA-approved and most people using it are doing so outside any supervised clinical setting. The "do actual research" kicker is well-intentioned but ironic, given that the video itself offers no sourced data.

What does the science actually show?

Retatrutide's phase 2 data, published by Jastreboff et al. (2023, NEJM), showed nausea in 45-58% of participants across dose groups, with the highest rates in titration phases. Vomiting hit around 20-30% in higher-dose cohorts. Fatigue was reported but was less systematically tracked as a standalone endpoint. The cold sensitivity she describes is less clearly documented in trials, though GLP-1 class drugs can affect thermoregulation indirectly via altered autonomic tone and reduced caloric intake. Blurry vision is where things get more complicated. It is not a listed common adverse event in the Jastreboff data, but the GLP-1 class broadly has an association with acute changes in refractive error, likely tied to rapid glycemic shifts and fluid changes in the lens, a pattern documented with semaglutide in case reports (Tran et al., 2023, Ophthalmology). Anyone experiencing visual changes on any GLP-1 or triple agonist should not wait it out.

Where does the social media noise diverge from clinical reality?

Here's the part that matters: every participant in the Jastreboff phase 2 trial was medically supervised, titrated on a structured schedule, and monitored for adverse events. The TikTok peptide pipeline operates entirely outside that structure. People are sourcing retatrutide from research chemical suppliers or compounding pharmacies with variable quality controls, often self-titrating based on forum advice rather than clinical guidance. The side effect profile someone experiences in that context is not comparable to trial data, because dose accuracy, purity, injection technique, and concurrent medications all affect outcomes in ways the trials controlled for. The "quiet side effects" framing in the caption is emotionally real but analytically incomplete. Some of what she's describing tracks with known GLP-1 class effects. Some of it, especially the blurry vision, warrants actual clinical evaluation rather than a TikTok caption. Calling it a "quiet" story implies the pharmaceutical industry is hiding something. The trial data is publicly available and the side effects are not hidden. What's hidden is the risk profile for unmonitored off-label use.

What should you actually know?

Retatrutide has no FDA approval as of mid-2025. It is not legally available as a prescribed drug in the United States. People using it are either obtaining it through research chemical channels, where purity and concentration cannot be guaranteed, or through compounded versions whose equivalency to the investigational compound used in trials cannot be assumed. The side effects this creator describes are consistent with GLP-1 class pharmacology at a general level, but that consistency does not mean her experience is predictable or safe without medical oversight. Cold intolerance may reflect reduced energy intake and altered metabolic rate. Nausea is well-documented. Fatigue during titration is common across the class. Blurry vision is the outlier here and should be evaluated by an eye care provider, not normalized in a TikTok comment section. The broader lesson: if your side effect protocol is "post about it and see who relates," you're operating without a safety net. These compounds have real pharmacological activity and real risk profiles.